{
    "root": "c0d7e550-fec4-42aa-9143-bc5600b8c3d3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Tadalafil",
    "value": "20221001",
    "ingredients": [
        {
            "name": "TADALAFIL",
            "code": "742SXX0ICT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_71940"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "indications": {
        "text": "tadalafil tablets phosphodiesterase 5 ( pde5 ) inhibitor indicated treatment : erectile dysfunction ( ed ) ( 1.1 ) signs symptoms benign prostatic hyperplasia ( bph ) ( 1.2 ) ed signs symptoms bph ( ed/bph ) ( 1.3 ) tadalafil tablets used finasteride initiate bph treatment , recommended 26 weeks ( 1.4 ) .",
        "doid_entities": [
            {
                "text": "erectile dysfunction (DOID:1875)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1875"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "split tadalafil tablets ; entire dose taken .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "tadalafil tablets , usp supplied follows : 2.5 mg light yellow , oval-shaped , film-coated tablets , debossed \u2018 08 \u2019 one side plain side . carton 30 tablets ( 2 blister cards 15 tablets ) ndc 0480-2308-65 5 mg pale yellow , oval-shaped , film-coated tablets , debossed \u2018 09 \u2019 one side plain side . carton 30 tablets ( 2 blister cards 15 tablets ) ndc 0480-2309-65 bottles 30 ndc 0480-2309-56 10 mg pale yellow , oval-shaped , film-coated tablets , debossed \u2018 10 \u2019 one side plain side . bottles 30 ndc 0480-2310-56 20 mg pale yellow , oval-shaped , film-coated tablets , debossed \u2018 11 \u2019 one side plain side . bottles 30 ndc 0480-2311-56",
    "adverseReactions": "nitrates concomitant nitrates form contraindicated [ ( 4.1 ) ] . alpha-blockers ed \u2014 tadalafil tablets coadministered alpha-blocker patients treated ed , patients stable alpha-blocker therapy prior initiating treatment , tadalafil tablets initiated lowest recommended dose [ ( 5.6 ) , ( 7.1 ) , pharmacology ( 12.2 ) ] . bph \u2014 tadalafil tablets recommended combination alpha-blockers treatment bph [ ( 5.6 ) , ( 7.1 ) , pharmacology ( 12.2 ) ] . cyp3a4 inhibitors tadalafil tablets needed \u2014 patients taking concomitant potent inhibitors cyp3a4 , ketoconazole ritonavir , maximum recommended dose tadalafil tablets 10 mg , exceed every 72 hours [ ( 5.10 ) ( 7.2 ) ] . tadalafil tablets daily \u2014 patients taking concomitant potent inhibitors cyp3a4 , ketoconazole ritonavir , maximum recommended dose 2.5 mg [ ( 5.10 ) ( 7.2 ) ] .",
    "indications_original": "Tadalafil tablets are a\u00a0phosphodiesterase\u00a05\u00a0(PDE5) inhibitor indicated\u00a0for\u00a0the treatment of: erectile\u00a0dysfunction\u00a0(ED) ( 1.1 ) the signs and\u00a0symptoms of\u00a0benign\u00a0prostatic\u00a0hyperplasia\u00a0(BPH) ( 1.2 ) ED and\u00a0the\u00a0signs and\u00a0symptoms of\u00a0BPH (ED/BPH) ( 1.3 ) If\u00a0tadalafil tablets\u00a0are\u00a0used\u00a0with finasteride\u00a0to\u00a0initiate\u00a0BPH\u00a0treatment,\u00a0such\u00a0use\u00a0is recommended\u00a0for up\u00a0to\u00a026\u00a0weeks ( 1.4 ).",
    "contraindications_original": "Do not split tadalafil tablets; entire dose should be taken.",
    "warningsAndPrecautions_original": "Tadalafil tablets, USP are supplied as follows: \n                        2.5 mg light yellow, oval-shaped, film-coated tablets, debossed with \u201808\u2019 on one side and plain on the other side. \n                        Carton of 30 tablets (2 blister cards of 15 tablets)\u00a0\u00a0\u00a0\u00a0 NDC 0480-2308-65\n                        5 mg pale yellow, oval-shaped, film-coated tablets, debossed with \u201809\u2019 on one side and plain on the other side.\n                        Carton of 30 tablets (2 blister cards of 15 tablets)\u00a0\u00a0\u00a0\u00a0 NDC 0480-2309-65\n                        Bottles of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 0480-2309-56\n                        10 mg pale yellow, oval-shaped, film-coated tablets, debossed with \u201810\u2019 on one side and plain on the other side.\n                        Bottles of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 0480-2310-56\n                        20 mg pale yellow, oval-shaped, film-coated tablets, debossed with \u201811\u2019 on one side and plain on the other side.\n                        Bottles of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 0480-2311-56",
    "adverseReactions_original": "Nitrates\n                  \n                  Concomitant use of nitrates in any form is contraindicated [see Contraindications (4.1)].\n                  \n                     Alpha-Blockers\n                     \n                  \n                  \n                     ED \u2014 When tadalafil tablets are coadministered with an alpha-blocker in patients being treated for ED, patients should be stable on alpha-blocker therapy prior to initiating treatment, and tadalafil tablets should be initiated at the lowest recommended dose [see Warnings and Precautions (5.6), Drug Interactions (7.1), and Clinical Pharmacology (12.2)].\n                  \n                     BPH \u2014 Tadalafil tablets are not recommended for use in combination with alpha-blockers for the treatment of BPH [see Warnings and Precautions (5.6), Drug Interactions (7.1), and Clinical Pharmacology (12.2)].\n                  \n                  \n                     CYP3A4 Inhibitors\n                  \n                  \n                     Tadalafil Tablets for Use as Needed \u2014 For patients taking concomitant potent inhibitors of CYP3A4, such as ketoconazole or ritonavir, the maximum recommended dose of tadalafil tablets is 10 mg, not to exceed once every 72 hours [see Warnings and Precautions (5.10) and Drug Interactions (7.2)].\n                  \n                     Tadalafil Tablets for Once Daily Use \u2014 For patients taking concomitant potent inhibitors of CYP3A4, such as ketoconazole or ritonavir, the maximum recommended dose is 2.5 mg\u00a0[see Warnings and Precautions (5.10) and Drug Interactions (7.2)].",
    "drug": [
        {
            "name": "Tadalafil",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_71940"
        }
    ]
}